pomalidomide (Pomalyst)
Jump to navigation
Jump to search
Indications
- treatment of multiple myeloma after progression of disease with lenalidomide & bortezomib treatment
Contraindications
Adverse effects
- neutropenia, anemia, thrombocytopenia
- venous thromboembolism[2]
- fatigue, weakness
- constipation, diarrhea
- upper respiratory tract infections
- back pain
- fever
Mechanism of action
- modulates immune system
- the other 2 drugs in this class, lenalidomide & thalidomide, are also angiogenesis inhibitors
More general terms
References
- ↑ FDA News Release: Feb. 8, 2013 FDA approves Pomalyst for advanced multiple myeloma ww.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm338895.htm
- ↑ 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022